

PUBLIKATIONSVERZEICHNIS

Klinik für Innere Medizin, Rheumatologie und Immunologie
Medius Kliniken
73207 Kirchheim unter Teck

A) WISSENSCHAFTLICHE PUBLIKATIONEN (Originalarbeiten in peer-review Journals)

1. Hellmich B, Gyermek L: NG-nitro-L-arginine methyl-ester: a muscarinic receptor antagonist? *Fundam Clin Pharmacol* 1997; 11(4): 305-14. **IF 1.717**
2. Hellmich B, Schnabel A, Gross WL: 64jährige Patientin mit Ruhedyspnoe und rasch progredienter Niereninsuffizienz. *Internist* 1998;39: 1062-1068. **IF 0.31**
3. Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome and systemic lupus erythematosus with granulocyte colony-stimulating factor. *Semin Arthritis Rheum* 1999;29:82-99. **IF 3.066**
4. Hellmich B, Schnabel A, Gross WL: Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. *Arthritis Rheum* 1999;42:1752-56. **IF 7.751**
5. Hellmich B, Schellner M, Schatz H, Pfeiffer A: Activation of Transforming Growth Factor- β_1 in Diabetic Kidney Disease. *Metabolism* 2000; 49:353-359. **IF 1.931**
6. Hellmich B, Csernok E, Trabandt A, Gross WL, Ernst M: Granulocyte macrophage-colony stimulating factor but not, granulocyte-colony stimulating factor, induces plasma membrane expression of proteinase 3 on neutrophils *in vitro*. *Clin Exp Immunol* 2000;120:392-398. **IF 2.805**
7. Meyer MF, Hellmich B, Kotterba S, Schatz H: Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? *Rheumatol Int* 2000; 20(1): 35-8. **IF 1.185**
8. Hellmich B, Ehren M, Lindstaedt M, Meyer M, Pfohl M, Schatz H: Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. *Clin Rheumatol* 2001; 20(6): 441-3. **IF 0.838**
9. Hering S, Jost C, Schulz H, Hellmich B, Schatz H, Pfeiffer H: Circulating transforming growth factor beta1 (TGFbeta1) is elevated by extensive exercise. *Eur J Appl Physiol* 2002; 86(5): 406-10. **IF 1.261**
10. Sanner BM, Tepel M, Esser M, Klewer J, Hoehmann-Riiese B, Zidek W, Hellmich B: Sleep-related breathing disorders impair quality of life in haemodialysis recipients. *Nephrol Dial Transplant* 2002; 17(7): 1260-5. **IF 2.432**
11. Sanner BM, Heise M, Knoblen B, Machnik M, Laufer U, Kikuth R, Zidek W, Hellmich B: MRI of the pharynx and treatment efficacy of a mandibular advancement device in obstructive sleep apnoea syndrome. *Eur Respir J* 2002; 20(1): 143-50. **IF 2.989**
12. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A: Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. *Arthritis Rheum* 2002; 46(9): 2384-91. **IF 7.751**
13. Hellmich B, Csernok E, de Haas M, von dem Borne AE, Schatz H, Gross WL, Schnabel A. Low Fcgamma receptor III and high granulocyte colony-stimulating factor serum levels correlate

- with the risk of infection in neutropenia due to Fely's syndrome or systemic lupus erythematosus. *Am J Med* 2002;113: 134-139. **IF 6.106**
14. Hellmich B, Schnabel A, Bauer T, Dorfmueller P, Schatz H: Interstitial pulmonary disease in systemic scleroderma: diagnosis. *Deut Med Wochenschr* 2002; 127(10): 517-9. **IF 0.704**
15. Hellmich B, Schnabel A, Bauer T, Schatz H: Interstitial pulmonary disease in systemic scleroderma: treatment. *Deut Med Wochenschr* 2002; 127(10): 520-2. **IF 0.704**
16. Meyer MF, Menken KU, Zimny S, Hellmich B, Schatz H: Pitfall in diagnosing growth hormone deficiency in a hypochondroplastic patient with a delayed puberty. *Exp Clin Endocrinol Diabetes* 2003; 111(3): 177-81. **IF 1.617**
17. Hellmich B, Hering S, Duchna HW, et al.: Airway manifestations of relapsing polychondritis: treatment with cyclophosphamide and placement of bronchial stents. *Z Rheumatol* 2003; 62(1): 73-9. **IF 0.765**
18. Csernok E, Holle J, Hellmich B, Cohen Tervaert JW, Kallenberg CGM, Limburg PC, Niles J, Pan G, Specks U, Westman K, Wieslander J, de Groot K, Gross WL. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies against proteinase-3 in Wegener's granulomatosis: First results from a multicenter study. *Rheumatology* 2004;43:174-178. **IF 4.045**
19. Aries PM, Hellmich B, Reinhold-Keller E, Gross WL. High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. *Rheumatology* (Oxford). 2004 Oct;43(10):1307-8. **IF 4.045**
20. Hellmich B, Ciaglo A, Schatz H, Coakley G. Autoantibodies against granulocyte-macrophage colony-stimulating factor and interleukin-3 are rare in patients with Felty's syndrome. *Ann Rheum Dis* 2004;63:862-866. **IF 6.411**
21. Metzler C, Hellmich B, Gause A, Gross WL, de Groot K: Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. *Clin Exp Rheumatol* 2004; 22: S52-61. **IF 1.614**
22. Metzler C, Lamprecht P, Hellmich B, Reuter M, Arlt AC, Gross WL. Leukencephalopathy after treatment of Churg-Strauss syndrome with interferon-alpha. *Ann Rheum Dis* 2005 64: 1242-1243 **IF 6.411**
23. Sordet C, Gottenberg JE, Hellmich B, Kieffer P, Mariette X, Sibilia J. Lack of efficacy of rituximab in Felty's syndrome. *Ann Rheum Dis*. 2005;64(2):332-3. **IF 6.411**
24. Holle J, Hellmich B, Backes M, Gross WL, Csernok E. Variations in performance characteristics of commercial enzyme immunoassay kits for the detection of antineutrophil cytoplasmic antibodies: What is the optimal cut-off? *Ann Rheum Dis* 2005;64 (12):1773-7. **IF 6.411**
25. Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg Strauss Syndrome. *Ann NY Acad Sci* 2005; 1051: 121-131 . **IF 1.593**
26. Meyer MF, Czaplewski H, Braun J, Hellmich B, Schatz H, Klein HH. Lack of a difference in increased capillary blood cell velocity in the skin over proximal interphalangeal joints between rheumatoid arthritis and osteoarthritis. *Microvasc Res*. 2005;70:1-6.] **IF 1.474**
27. Jagiello P, Aries PM, Arning L, Csernok E, Hellmich B, Wagenleiter SEN, Gross WL, Epplen JT. The *PTPN22* 620W allele is a risk factor for Wegener's granulomatosis. *Arthritis Rheum* 2005; 52: 4039-43. **IF 7.751**

28. Aries PM, Hellmich B, Both M, Nolle B, Voswinkel J, Holl-Ulrich K, Lamprecht P, Gross WL. Lack of efficacy of Rituximab in Wegener's Granulomatosis with refractory granulomatous manifestations. *Ann Rheum Dis* 2006;65:853-858. **IF 6.411**.
29. Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. *Eur J Clin Invest*. 2006 Sep;36 Suppl 3:44-8. **IF 2.684**
30. Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, Lamprecht P, Holle JU, Hellmich B. Wegener's autoantigen induces maturation of dendritic cells and licences them for th1 priming via the protease-activated receptor-2 pathway. *Blood* 2006;107:4440-4448. IF 10.896
31. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen Tervaert JW, Scott DG. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis*. 2007;66:222-227. **IF 6.411**
32. Ahmadi-Simab K, Hellmich B, Holl-Ulrich K, Fleischmann C, O. Dourvos O, Gross WL. Acute Coronary Syndrome in Takayasu Arteritis without elevation of acute phase parameters. *Rheumatology* 2007;46:554-555 . **IF 4.226**
33. Hellmich B, Flossmann O, Gross W, Bacon P, Cohen-Tervaert J, Guillevin L, Jayne D, Mahr A, Merkel P, Raspe H, Scott D, Witter J, Yazici H, Luqmani R: EULAR Recommendations for Conducting Clinical Studies and/or Clinical Trials in Systemic Vasculitis: Focus on ANCA-associated vasculitis. *Ann Rheum Dis* 2007; 66:605-17. IF 6.411
34. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, Gross WL, Reinhold-Keller E. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis *Rheumatology* (Oxford). 2007 Jul;46(7):1087-91
35. Meyer MF, Schmidt O, Hellmich B, Schatz H, Klein HH, Braun J Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations *Rheumatol Int*. 2007 Dec;28(2):145-52
36. Hellmich B, Csernok E, Fredenhagen G, Gross WL. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. *Clin Exp Rheumatol*. 2007;25 (1 Suppl 44):1-5. IF 1.644
37. Lange C, Hellmich B, Ernst M, Ehlers S. Rapid diagnosis of tuberculosis by a T cell interferon-gamma release assay on pleural fluid mononuclear cells in a woman undergoing anti-TNF therapy. *Nature Clinical Practice Rheumatology* 2007 Sep;3(9):528-34. **IF 3,812**
38. Mukhtyar C, Flossmann O, Hellmich B, Bacon PA, Cid MC, Cohen Tervaert JW, Gross WL, Guillevin L, Jayne DR, Mahr A, Merkel PA, Raspe H, Scott DG, Witter J, Yazici H, Luqmani RA Outcomes from studies of Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the EULAR Systemic Vasculitis Task Force. *Ann Rheum Dis*. 2008; 67: 1004-10 **IF 6.411**
39. Wieczorek S, Hellmich B, Gross WL, Eppelen JT. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides. *Arthritis Rheum*. 2008 Jan;58(1):329-30. **IF 7.751**

40. Heckmann M, Holle JU, Arning L, Knaup S, Hellmich B, Nothnagel M, Jagiello P, Gross WL, Epplen JT, Wiczorek S. The Wegener's Granulomatosis quantitative trait locus on chromosome 6p21.3 as characterized by tagSNP genotyping. *Ann Rheum Dis*. 2008; 67: 1004-10. **IF 6.411**
41. Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, Guillevin L, Hellmich B. The leukotriene-receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. *Thorax*. 2008; 63: 677-82. IF 6.226
42. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators: Tate G, Maldonado-Cocco JA, Scali J, Taylor A, Hanrahan P, Nash P, Smith M, Smolen J, Koeller M, Smolen J, Eberl G, Dunky A, Zamani O, Simon JC, Scheinberg MA, Yaneva D, Oparanov B, Karastatev D, Atkins C, Beaulieu A, Bell M, Haraoui B, Marin L, Thorne JC, Zimmer M, Khraishi M, McKendry RJ, Pandith V, McCarthy T, Lau CS, Li E, Mok CC, Kahan A, Wendling D, Bardin T, Nguyen M, Claudepierre P, Berenbaum F, Puechal X, Alten R, Fiehn C, Heilig B, Hellmich B, Lange U, Lorenz HM, Rubbert-Roth A, Wendler J, Czirikak L, Hodinka L, Szekanecz Z, Molad Y, Nahir M, Rosner I, Rubinow A, Abu Shakra M, Elkayam O, Marcolongo R, Bagnato G, Triolo G, Trotta F, de Vita S, Ramos-Remus C, Lugo GE, Abud-Mendoza C, Pineca C, de la Torre IG, Pacheco C, Leong KH, Koh DR, Rovensky J, Dudler J, Villiger P, Lothrenoo W, Asavatanabodee P, Nilganuwong S, Totemchokchaiyakarn K. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet*. 2008 Mar 22;371(9617):987-97. **IF 28.600**
43. Metzler C, Schnabel A, Gross WL, Hellmich B. A Phase II study of interferon-alpha for treatment of refractory Churg-Strauss syndrome. *Clin Exp Rheumatol* 2008;26:S35-40. IF 1.644
44. Flossmann O, Baslund B, Bruchfeld A, Cohen Tervaert JW, Hall C, Heinzl P, Hellmich B, Luqmani RA, Nemoto K, Tesar V, Jayne DR. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. *Ann Rheum Dis*. 2008 Aug 19. [Epub ahead of print] **IF 6.411**
45. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R. EULAR Recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis*. 2008 Apr 15. [Epub ahead of print] **IF 6.411**
46. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R. EULAR Recommendations for the management of large vessel vasculitis. *Ann Rheum Dis*. 2008 Apr 15. [Epub ahead of print] **IF 6.411**
47. Polzer K, Karonitsch T, Neumann T, Eger G, Haberler C, Soleiman A, Hellmich B, Csernok E, Distler J, Manger B, Redlich K, Schett G, Zwerina J. Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely correlating with disease activity. *Rheumatology (Oxford)*. 2008 Jun;47(6):804-8. **IF 4.045**
48. Wiczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, Epplen JT. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. *Arthritis Rheum* 2008 Jun;58(6):1839-48. **IF 7.751**

49. Merkel PA, Cuthbertson DD, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, Krischer JP, Luqmani R, Mahr AD, Matteson EL, Specks U, Stone JH. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. *Ann Rheum Dis*. 2009 Jan;68(1):103-6. **IF 6.411**
50. Herlyn K, Hellmich B, Seo P, Merkel PA Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. *Arthritis Care Res* 2010 Nov;62(11):1639-45.
51. Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg Strauss Syndrome. A long-term observational study. *Clin Exp Rheumatol* 2010; 28: 24-30
52. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C. The risk of tuberculosis related to tumor necrosis factor antagonists: a TBNET consensus statement. *Eur Resp J* 2010; 36: 1185-1206.
53. Laudien M, Gadola SD, Podschun R, Hedderich J, Paulsen J, Reinhold-Keller E, Csernok E, Ambrosch P, Hellmich B, Moosig F, Gross WL, Sahly H, Lamprecht P. Nasal Carriage of staphylococcus aureus an enodnasal activity in Wegeners granulomatosis as compared to rheumatoid arthritis an nasal polyyps. *Clin Exp Rheumatol*. 2010 Jan-Feb;28(1 Suppl 57):51-5.
54. Laskari K, Ahmadi-Simab K, Lamken M, Csernok E, Gross WL, Hellmich B. Are anticyclic citrullinated autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis? *Ann Rheum Dis*. 2010 Feb;69(2):469-71.
55. Dwivedi N, Upadhyay J, Neeli I, Khan S, Pattanaik D, Myers L, Kirou KA, Hellmich B, Knuckley B, Thompson PR, Crow MK, Mikuls TR, Csernok E, Radic M. Felty's syndrome autoantibodies bind to deiminated histones and neutrophil extracellular traps. *Arthritis Rheum*. 2011 Oct 27. doi: 10.1002/art.33432. [Epub ahead of print
56. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. *Ann Intern Med*. 2011 Sep 6;155(5):341-3.
57. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2011 Jan;70(1):32-8.
58. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016 Sep;75(9):1583-94

59. Csernok E, Damoiseaux J, Rasmussen N, Hellmich B, van Paassen P, Vermeersch P, Blockmans D, Cohen Tervaert JW, Bossuyt X. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). *Autoimmun Rev.* 2016 Jul;15(7):736-41.
60. Clowse ME, EMBODY Investigator Group..Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. *Arthritis Rheumatol.* 2017 Feb;69(2):362-375.
61. Wechsler ME, Akuthota P, Jayne D et al. ; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. *N Engl J Med.* 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079.
62. Bossuyt X, Rasmussen N, van Paassen P, Hellmich B, Baslund B, Vermeersch P, Blockmans D, Cohen Tervaert JW, Csernok E, Damoiseaux J. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies. *Rheumatology (Oxford).* 2017 Sep 1;56(9):1533-1541
63. Rasmussen N, Damoiseaux J, Csernok E, Heegaard NHH, Hellmich B, Paassen PV, Baslund B, Vermeersch P, Blockmans D, Tervaert JC, Bossuyt X. Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assays. *Clin Chem Lab Med.* 2018 Jan 26;56(2):e39-e42.
64. Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C. Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. *RMD Open.* 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449.
65. Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. *Nat Rev Rheumatol.* 2017 Nov;13(11):683-692. doi: 10.1038/nrrheum.2017.140.
66. Schirmer JH, Aries PM, de Groot K, Hellmich B, Holle JU, Kneitz C, Kötter I, Lamprecht P, Müller-Ladner U, Reinhold-Keller E, Specker C, Zänker M, Moosig F. S1 Leitlinie zur Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. *Z Rheumatol.* 2017 Nov;76(Suppl 3):77-104. doi: 10.1007/s00393-017-0394-1.
67. Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaefferbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. *Ann Rheum Dis.* 2018 77(6):840-847.
68. Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA; BREVAS Study Collaborators (B. Hellmich). Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. *Arthritis Rheumatol.* 2019 Jun;71(6):952-963.
69. Monti S, Agueda AF, Luqmani R, Buttgerit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt WA, Hellmich B. Systematic literature review informing the 2018 update of the EULAR recommendations for the management of large vessel vasculitis: focus on giant cell arteritis. *RMD open* 2019; RMD Open 5(2):e001003

70. Agueda A, Monti S, Luqmani R, Buttgereit F, Cid M, Dasgupta B, Dejaco C, Mahr A, Ponte C, Salvarani C, Schmidt WA, Hellmich B. Management of Takayasu arteritis: a systematic review informing the 2018 update of the EULAR recommendations for the management of large vessel vasculitis. *RMD open* 2019; 5(2):e001020
71. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis*. 2020; 79(1):19-30
72. Bossuyt X, Damoiseaux J, Rasmussen N, van Paassen P, Hellmich B, Baslund B, Blockmans D, Vermeersch P, Lopez-Hoyos M, Vercammen M, Barret E, Hammar F, Leinfelder U, Mahler M, Olschowka N, Roggenbuck D, Schlumberger W, Walker R, Rönnelid J, Cohen Tervaert JW, Csernok E, Fierz W; for (i) the European Federation of Laboratory Medicine (EFLM) Task and Finish Group "Autoimmunity Testing," (ii) the European Autoimmune Standardization Initiative (EASI) and the (iii) European Consensus Finding Study Group on autoantibodies (ECFSG). Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper. *Clin Chem Lab Med*. 2020 Oct 16;59(2):e35-e39.
73. Moiseev S, Bossuyt X, Arimura Y, Blockmans D, Csernok E, Damoiseaux J, Emmi G, Flores-Suárez LF, Hellmich B, Jayne D, Jennette JC, Little MA, Mohammad AJ, Moosig F, Novikov P, Pagnoux C, Radice A, Sada KE, Segelmark M, Shoenfeld Y, Sinico RA, Specks U, Terrier B, Tzioufas AG, Vaglio A, Zhao MH, Cohen Tervaert JW; European EGPA Study Group. International Consensus on ANCA Testing in Eosinophilic Granulomatosis With Polyangiitis. *Am J Respir Crit Care Med* 2020 Jun 25. doi: 10.1164/rccm.202005-1628SO.
74. Schirmer JH, Aries PM, Balzer K, Berlit P, Bley TA, Buttgereit F, Czihal M, Dechant C, Dejaco C, Garske U, Henes J, Holle JU, Holl-Ulrich K, Lamprecht P, Nölle B, Moosig F, Rech J, Scheuermann K, Schmalzing M, Schmidt WA, Schneider M, Schulze-Koops H, Venhoff N, Villiger PM, Witte T, Zänker M, Hellmich B. S2k Leitlinie: Management der Großgefäßvaskulitiden *Z Rheumatol*. 2020 Nov;79(Suppl 3):67-95.
75. Löffler C, Mahrhold J, Fogarassy P, Beyer M, Hellmich B. Two immunocompromised patients with diffuse alveolar hemorrhage as a complication of severe COVID-19. *Chest* 2020 58(5):e215-e219.
76. Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group (incl. B. Hellmich). Avacopan for the Treatment of ANCA-Associated Vasculitis. *N Engl J Med*. 2021 Feb 18;384(7):599-609.
77. Laskari K, Hellmich B, Adamus G, Csernok E. Autoantibody profile in eosinophilic granulomatosis and polyangiitis: predominance of anti-alpha-enolase antibodies. *Clin Exp Rheumatol*. 2021 Mar-Apr;39 Suppl 129(2):83-87.
78. Iking-Konert C, Wallmeier P, Arnold S, Adler S, de Groot K, Hellmich B, Hoyer BF, Holl-Ulrich K, Ihorst G, Kaufmann M, Kötter I, Müller-Ladner U, Magnus T, Rech J, Schubach F, Schulze-Koops H, Venhoff N, Wiech T, Villiger P, Lamprecht P. The Joint Vasculitis Registry in German-speaking countries (GeVas) - a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. *BMC Rheumatol*. 2021 Jul 31;5(1):40. doi: 10.1186/s41927-021-00206-2
79. Papo M, Sinico RA, Teixeira V, Venhoff N, Urban ML, Iudici M, Mahrhold J, Locatelli F, Cassone G, Schiavon F, Seeliger B, Neumann T, Kroegel C, Groh M, Marvisi C, Samson M, Barba T, Jayne D, Troilo A, Thiel J, Hellmich B, Monti S, Montecucco C, Salvarani C, Kahn JE, Bonnotte B, Durel CA, Puéchal X, Mouthon L, Guillevin L, Emmi G, Vaglio A, Terrier B; French Vasculitis Study Group and the EGPA European Study Group. Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *Rheumatology (Oxford)*. 2021 Sep 1;60(9):4355-4360.

80. Kempiners N, Mahrhold J, Hellmich B, Csernok E. Evaluation of PR3- and MPO-ANCA line and dot immunoassays in ANCA-associated vasculitis. *Rheumatology* (Oxford). 2021 Sep 1;60(9):4390-4394.
81. Hellmich B, Lamprecht P, Spearpoint P, Götte D, Deichmann A, Buchholz I, Schönermark MP, Rutherford P. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. *Rheumatology* (Oxford). 2021 Oct 2;60(10):4868-4873.
82. Bettiol A, Urban ML, Dagna L, Cottin V, Franceschini F, Del Giacco S, Schiavon F, Neumann T, Lopalco G, Novikov P, Baldini C, Lombardi C, Berti A, Alberici F, Folci M, Negrini S, Sinico RA, Quartuccio L, Lunardi C, Parronchi P, Moosig F, Espígol-Frigolé G, Schroeder J, Kernder AL, Monti S, Silvagni E, Crimi C, Cinetto F, Fraticelli P, Roccatello D, Vacca A, Mohammad AJ, Hellmich B, Samson M, Bargagli E, Cohen Tervaert JW, Ribí C, Fiori D, Bello F, Fagni F, Moroni L, Ramirez GA, Nasser M, Marvisi C, Toniati P, Firinu D, Padoan R, Egan A, Seeliger B, Iannone F, Salvarani C, Jayne D, Prisco D, Vaglio A, Emmi G; European EGPA Study Group. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. *Arthritis Rheumatol*. 2022 Feb;74(2):295-306.
83. Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, Khalid S, Hutchings A, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group (incl. B. Hellmich). 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. *Arthritis Rheumatol*. 2022 Mar;74(3):386-392.
84. Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, Judge A, Hutchings A, Merkel PA, Luqmani RA, Watts RA; DCVAS Study Group (incl. B. Hellmich). 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. *Arthritis Rheumatol*. 2022 Mar;74(3):400-406.
85. Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA; DCVAS Study Group (incl. B. Hellmich). 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. *Arthritis Rheumatol*. 2022 Mar;74(3):393-399.
86. Pouchelon C, Visentini M, Emmi G, le Guern V, Quartuccio L, Samson M, Venhoff N, Briantais A, Casato M, Chatelus E, Chilles M, Cid MC, Diot E, Ebbo M, Faguer S, Hellmich B, Jachiet M, Moulinet T, Perrin F, Quémeneur T, Sinico RA, Terrier B. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. *Autoimmun Rev*. 2022 Apr;21(4):103034. doi: 10.1016/j.autrev.2022.103034.
87. Conticini E, Hellmich B, Frediani B, Csernok E, Löffler C. Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis. *Scand J Rheumatol*. 2022 Apr 6:1-7.
88. Cid MC, Unizony SH, Blockmans D, Brouwer E, Dagna L, Dasgupta B, Hellmich B, Molloy E, Salvarani C, Trapnell BC, Warrington KJ, Wicks I, Samant M, Zhou T, Pupim L, Paolini JF; KPL-301-C001 Investigators. Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. *Ann Rheum Dis*. 2022 May;81(5):653-661.
89. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Watts RA, Merkel PA, Luqmani RA; DCVAS Study Group (incl. B. Hellmich). 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. *Ann Rheum Dis*. 2022 Dec;81(12):1647-1653.
90. Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, Craven A, Khalid S, Hutchings A, Danda D, Luqmani RA, Watts RA, Merkel PA; DCVAS Study Group (incl. B. Hellmich). 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. *Ann Rheum Dis*. 2022 Dec;81(12):1654-1660.

b) Übersichtsarbeiten

1. Hellmich B, Gross WL: Zwischen "Off-label" Verordnung und "unterlassener Hilfeleistung": der Rheumatologe zwischen Scylla und Charybdis. *Z Rheumatol* 2003; 62(1): 34-5. **IF 0.765**
2. Hellmich B, Csernok E, Gross W: 20 Years with ANCA (antineutrophil cytoplasmic antibodies): from seromarker to major pathogenic player in vasculitis. *J Leukocyte Biol* 2003; 74(1): 1-2. **IF 4.516**
3. Hellmich B, Gross WL. Recent Advances in the Treatment of Rheumatic diseases. The fourth Annual Congress of Rheumatology. *Exp Opin Invest Drug* 2003;12:1713-1719. **IF k.A.**
4. Hellmich B, Ehlers S, Csernok E, Gross W: Update on the pathogenesis of Churg-Strauss syndrome. *Clin Exp Rheumatol* 2003;21: S69-77. **IF 1.614**
5. Hellmich B, Gross WL: Churg-Strauss syndrome following treatment with leukotriene receptor antagonists: demasking by steroid taper or side effect?. *Dtsch Med Wochenschr* 2003; 128(27): 1469. **IF 0.704**
6. de Groot K, Gross WL, Hellmich B. Therapie der primär systemischen Vaskulitiden *Internist* 2003;44(12):1541-1548. **IF 0.31**
7. Hellmich B, Gross WL. Recent developments in the treatment of Rheumatic Diseases. The fourth Annual Congress of Rheumatology. *Exp Opin Invest Drug* 2003;12: 1713-1719. **IF k.A.**
8. Gross WL, Hellmich B. Riesenzellarteriitis. *Dtsch Med Wschr* 2003;128: 2604-2607. **IF 0.704**
9. Hellmich B, Gross WL. Recent Progress in the Pharmacotherapy in Churg-Strauss syndrome. *Exp Opin Pharmacotherap* 2004;5:25-35.
10. Hellmich B, Voswinkel J, Gross WL. Primäre systemische Vaskulitiden: Wege zur Diagnose. *Dtsch Med Wschr* 2004; 129: 1322-1327. **IF 0.704**
11. Gottschlich S, Ambrosch P, Gross WL, Hellmich B. Morbus Wegener im Kopf/Hals Bereich. *HNO*. 2004 Oct;52 (10):935-45. **IF 0.62**
12. Hellmich B, Epplen JT, Gross WL: Are ANCA-associated vasculitides inherited? *Clin Exp Rheumatol* 2004; 22(6 Suppl 36): S1-2. **IF 1.644**
13. Hellmich B, Kausch I, Doehn C, Jocham D, Holl-Ulrich K, Gross WL: Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide? *Ann Rheum Dis* 2004; 63(10): 1183-5. **IF 6.956**
14. Schnabel A, Hellmich B, Gross WL. Interstitial lung disease in polymyositis and dermatomyositis. *Curr Rheumatol Rep*. 2005 Apr;7(2):99-105. **IF k.A.**
15. Hellmich B, Merkel F, Weber M, Gross WL. Frühdiagnose entzündlicher Systemerkrankungen. *Internist* 2005; 46: 421-432. **IF 0.31**
16. Hellmich B, Gross W: Difficult to diagnose manifestations of vasculitis: does an interdisciplinary approach help? *Bailleres Best Pract Res Clin Rheumatol* 2005; 19: 243-261. **IF 0.789**
17. Gross W, Hellmich B. Preface. *Best Pract Res Clin Rheumatol* 2005;19:vi-vii. **IF 0.789**

18. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence? *Clin Rev Allergy Immunol*. 2005 Dec;29(3):237-45. **IF 0.931**
19. Merkel PA, Seo P, Aries P, Neogi T, Villa-Forte A, Boers M, Cuthbertson D, Felson DT, Hellmich B, Hoffman GS, Jayne DR, Kallenberg CG, Krischer J, Mahr A, Matteson EL, Specks U, Luqmani R, Stone J; Vasculitis Clinical Research Consortium; OMERACT 7 Special Interest Group. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. *J Rheumatol*. 2005 Dec;32(12):2488-95. **IF 2.591**
20. Hellmich B, Lamprecht P, Gross WL. Rheumatologie – auf der Suche nach dem individuellen therapeutischen Cocktail. *Dtsch Med Wochenschr* 2005; 130: 1555-1558. **IF 0.704**
21. Hellmich B, Pinals RS, Loughran TP Jr, Sullivan KE. New Clues to accrue on neutropenia in rheumatoid arthritis. *Clin Immunol* 2005;117; 1-5. **IF 2.761**
22. Hellmich B, Gross WL. Polymyalgia rheumatica. Myalgisches Syndrom oder okkulte Vaskulitis? *Internist (Berl)*. 2005; 46: 1233-44. **IF 0.31**.
23. Hellmich B, Lamprecht P, Aries PM, Gross WL: Frühdiagnose der Vaskulitiden. *Z Rheumatol* 2005: 64: 538-46. **IF 0.765**
24. Metzler C, Hellmich B, Gause A. Neue therapeutische Konzepte bei Vaskulitiden und Kollagenosen. ? *Internist (Berl)*. 2005; 46: 1347-53. **IF 0.31**.
25. Ahmadi K, Hellmich B, Gross WL. Wie Sie das Raynaud Syndrom erkennen und behandeln. *MMW-Fortschr-Med*. 2006;;55-56. **IF k.A.**
26. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. *Curr Opin Rheumatol* 2006; 18: 25-32.
27. Ahmadi-Simab K, Hellmich B, Lamprecht P, Gross WL. Update Rheumatologie Teil III Aktuelle Forschungsergebnisse zur Epidemiologie, Diagnose und Therapie von Kollagenosen. *Med Klin* 2006; 101: 127-137. **IF 0.31**
28. Lamprecht P Ahmadi-Simab K, Gross WL Hellmich B.(2006) Update Rheumatologie Teil III. Aktuelle Forschungsergebnisse zur Epidemiologie, Diagnose und Therapie von primär systemischen Vaskulitiden. *Med Klin* 101:212-225. **IF 0.31**
29. Aries P, Hellmich B, Gross WL. Diagnose und Therapie der ANCA-assoziierten Vaskulitiden. *Dtsch Med Wochenschr*. 2006; 131: 443-46. **IF 0.704**
30. Hellmich B, Metzler C, Gross WL. Churg-Strauss Syndrom: Aktueller Stand in Diagnostik und Therapie. *Dtsch Med Wochenschr*. 2006; 131: 2270-2274. **IF 0.704**
31. Mukthyar C, Hellmich B, Janje D, Flossman O, Luqmani R. Remission in antineutrophil cytoplasmic antibody-associated vasculitis. *Clin Exp Rheumatol* 2006;24:S093-98. **IF 1.644**
32. Gottschlich S, Ambrosch P, Kramkowski D, Laudien M, Buchelt T, Gross WL, Hellmich B. Head and neck manifestations of Wegener's granulomatosis. *Rhinology*. 2006 Dec;44(4):227-33. **IF 0,621**
33. Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, Jayne D, Kallenberg CG, Langford CA, Mahr A, Matteson EL, Mukthyar CB, Neogi T, Rutgers A, Specks U, Stone JH,

- Ytterberg SR, Merkel PA. The future of damage assessment in vasculitis. *J Rheumatol*. 2007 Jun;34(6):1357-71. **IF 2.591**
34. Nataraja A, Mukhtyar C, Hellmich B, Langford C, Luqmani R. Outpatient assessment of systemic vasculitis. *Best Pract Res Clin Rheumatol*. 2007 Aug;21(4):713-32. **IF 0.789**
35. Hellmich B, Holl-Ulrich K, Gross WL. Hypereosinophilic syndrome--recent developments in diagnosis and treatment. *Dtsch Med Wochenschr*. 2007 Sep;132(37):1892-6. **IF 0.704**
36. Hellmich B, Holl-Ulrich K, Merz H, Gross WL. Hypereosinophiles Syndrom und Churg-Strauss Syndrom: Ist die Differenzierung der Syndrome klinische relevant?. *Internist* 2008 Jan 25; 49: 286-296. **IF 0.31**
37. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R. EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis*. 2009 Mar;68(3):318-23. **IF 6.411**
38. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis*. 2009 Mar;68(3):310-7. **IF 6.411**
39. Hellmich B. Inflammatory Vascular Diseases. In: *Vascular Medicine* (Hrsg: Cissarek, Kröger, Santosa), ABW Wissenschaftsverlag 2010, Seite 356-390.
40. Hellmich B. Update on the Management of Systemic Vasculitis: What did we learn in 2009? *Clin Exp Rheumatol* 2010; 28: 98-103
41. Hellmich B, Palme R, Ade T, Leschke M. die klinische Visite und das ärztliche Gespräch. *Kliniker* 2010; 39: 344-48.
42. Krüger K, Hellmich B, Rubbert-Roth A, Müller-Ladner U, Kielhorn A. [Is it possible to compare different studies on efficacy of biologicals in patients with rheumatoid arthritis? : mixed treatment comparison as a new tool for indirect comparison of clinical studies]. *Z Rheumatol*. 2011 Aug;70(6):517-24.
43. Fleck M, Hellmich B. Vasculitis 2011 Update. *Dtsch Med Wochenschr*. 2011 Jun;136(22):1194-6.
44. Hellmich B, Fleck M. Update Vaskulitis 2012. *Dtsch Med Wochenschr*. 2012 Jun;137(22):1188-91.
45. Hellmich B, de Groot K. Kryoglobulinämische Vaskulitis. *Der Nephrologe* 2012; 7: 209-220.
46. Fleck M, Hellmich B. Vasculitis. *Dtsch Med Wochenschr*. 2013 Jun;138(23):1236-9
47. Guillevin L,; DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. *Clin Exp Rheumatol*. 2013 Mar-Apr;31(2 Suppl 76):71-80.
48. Hellmich B. Muscular diseases. *Z Rheumatol*. 2013 Apr;72(3):207-

49. Moosig F, Aries PM, de Groot K, Haubitz M, Hellmich B, Iking-Konert C, Wagner AD, Zänker M. B-cell targeted therapy in patients with granulomatosis with polyangiitis and microscopic polyangiitis. *Dtsch Med Wochenschr*. 2014 Oct;139(44):2248-53.
50. Hellmich B. Remission induction in ANCA-associated vasculitis: Follow-up data of the RAVE study. *Z Rheumatol*. 2014 Mar;73(2):194-5.
51. Henes J, Hellmich B. Frühdiagnose der Rheumatoiden Arthritis – ein Update. *Der Hausarzt* 2015
52. Hellmich B, Lamprecht P, Moosig F. Vaskulitiden *Z Rheumatol*. 2015 Dec;74(10):852-3
53. Walz B, Hellmich B. Fieber, Hautveränderungen und Myalgien: Vom Frühsymptom zur Diagnose. *Dtsch Med Wochenschr*. 2015 Jul;140(15):1137-44.
54. Hellmich B. Therapiestrategien bei ANCA-assoziierten Vaskulitiden *Z Rheumatol*. 2015 Jun;74(5):388-97.
55. Hellmich B. Remission maintenance with methotrexate, azathioprine or mycophenolate-mofetil after induction therapy with rituximab for granulomatosis with polyangiitis. *Z Rheumatol*. 2015 Mar;74(2):157-8.
56. Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kötter I, Krüger K, Lakomek J, Lorenz HM, Manger B, Märker-Hermann E, Minden K, Müller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Rütger W, Schett G, Schuch F, Schulze-Koops H, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M. Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga". *Z Rheumatol*. 2016 May;75(4):416-28.
57. Riemekasten G, Aringer M, Baerwald CG, Meyer-Bahlburg A, Bergner R, Feuchtenberger M, Gebhardt C, Hellmich B, Keyßer G, Lorenz HM, Kneitz C, Witte T, Müller-Ladner U, Schneider M, Braun J, Rautenstrauch J, Specker C, Schulze-Koops H. Rheumatology - Integration into student training (RISA) : Current structure of clinical rheumatology in German universities (RISA III)]. *Z Rheumatol*. 2016 Jun;75(5):493-501
58. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016 Sep;75(9):1583-94
59. Hellmich B. Management of polymyalgia rheumatica and large vessel vasculitis. *Internist (Berl)*. 2016 Nov;57(11):1069-1078.
60. Hellmich B. Current guidelines on ANCA-associated vasculitides : Common features and differences]. *Z Rheumatol*. 2017 Mar;76(2):133-142.
61. Csernok E, Kempiners N, Hellmich B. Paradigm shift in ANCA diagnostics : New international consensus recommendations. *Z Rheumatol*. 2017 Mar;76(2):143-148.
62. Zink A, Hellmich B. Evidence-based guidelines : Cookbook medicine or key to better care? *Z Rheumatol*. 2017 Mar;76(2):102-103.

63. Csernok E, Mahrhold J, Hellmich B. Anti-neutrophil cytoplasm antibodies (ANCA): Recent methodological advances-Lead to new consensus recommendations for ANCA detection. *J Immunol Methods*. 2018 May;456:1-6.
64. Hellmich B, Moosig F. Eosinophile Erkrankungen in der Rheumatologie [Eosinophilic diseases in rheumatology]. *Z Rheumatol*. 2019;78(4):304-305.
65. Henes JC, Wirths S, Hellmich B. Differentialdiagnose der Hypereosinophilie [Differential diagnosis of hypereosinophilia]. *Z Rheumatol*. 2019;78(4):313-321.
66. Hellmich B. ANCA-assozierte Vaskulitiden: State of the Art [ANCA-associated vasculitides : State of the art]. *Z Rheumatol*. 2019 78(6):518-528
67. Marvisi C, Sinico RA, Salvarani C, Jayne D, Prisco D, Terrier B, Emmi G, Vaglio A; European EGPA Study Group (B. Hellmich). New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. *Intern Emerg Med*. 2019; 14(8):1193-1197
68. Edelmann E, Lakomek HJ, Bessler F, Braun J, Froschauer S, Hellmich B, von Hinüber U, Kalthoff L, Karberg K, Kekow J, Krause A, Müller-Brodmann W, Munte A, Ruehlmann JM, Zinke S. Ambulante spezialärztliche Versorgung (ASV) – eine neue Versorgungsform in der Rheumatologie [Outpatient specialist medical treatment (ASV)-a new treatment level in rheumatology]. *Z Rheumatol*. 2019 Oct;78(8):765-773.
69. Hellmich B, Löffler C. Was sind die Indikationen für Rescue Prozeduren? Rheumatische Systemerkrankungen auf der Intensivstation . *Z Rheumatol*. 2019 78(10):955-966
70. de Groot K, Aries PM, Haubitz M, Hellmich B, Lamprecht P, Thiel J. Anti-B-Zell-Antikörpertherapie zur Remissionserhaltung bei GPA und MPA [Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis]. *Dtsch Med Wochenschr*. 2020 Jan;145(1):40-46.
71. Horvath L, Hellmich B. Therapie der Riesenzellarteriitis und Polymyalgia rheumatica [Treatment of giant cell arteritis and polymyalgia rheumatica]. *Z Rheumatol*. 2020 Mar;79(2):175-185.
72. Csernok E, Hellmich B. Usefulness of vasculitis biomarkers in the era of the personalized medicine. *Autoimmun Rev*. 2020 May;19(5):102514. doi: 10.1016/j.autrev.2020.102514. Epub 2020 Mar 12
73. Hellmich B. Therapie der Takayasu Arteriitis [Treatment of Takayasu arteritis]. *Z Rheumatol*. 2020 May 19. doi: 10.1007/s00393-020-00806-2. Online ahead of print
74. Hellmich B, Águeda AF, Monti S, Luqmani R. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. *Curr Rheumatol Rep*. 2020 Oct 12;22(12):84.
75. Csernok E, Hellmich B. ANCA Diagnostik bei Vaskulitiden [ANCA diagnostics in vasculitis]. *Z Rheumatol*. 2020 Jun 2. doi: 10.1007/s00393-020-00805-3. Online ahead of print
76. Hellmich B. Wie ich behandle: ANCA-assozierte Vaskulitiden nach Erreichen einer Remission [ANCA-associated vasculitis after achieving remission]. *Z Rheumatol*. 2020 Jun 25. doi: 10.1007/s00393-020-00828-w.
77. Lakomek HJ, Krause A, Braun J, Hellmich B, Klass M, Lorenz H, Schneider M, Schulze-Koops H, Specker C. Future of acute inpatient rheumatology in Germany : Statement of the Boards of the German Society for Rheumatology and the Association of Rheumatological Acute Clinics on hospital planning North-Rhine/Westphalia 2019 for the discipline rheumatology. *Z Rheumatol*. 2021 Feb;80(1):103-106.
91. Lakomek HJ, Rudwaleit M, Hentschel A, Broge B, Abrolat J, Bessler F, Hellmich B, Klemann A, Krause A, Klass M, Strunk J, Fiori W, Roeder N, Braun J. Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics]. *Z Rheumatol*. 2021 Oct;80(8):758-770.
92. Hellmich B. Glucocorticoids in the treatment of giant cell arteritis : How much, how long and how to spare?. *Z Rheumatol*. 2021 May;80(4):322-331.
93. Kraemer M, Becker J, Bley TA, Steinbrecher A, Minnerup J, Hellmich B. Diagnostics and treatment of giant cell arteritis. *Nervenarzt*. 2021 Nov 3. doi: 10.1007/s00115-021-01216-8.

94. Hellmich B, Buttgereit F. GCA management guidelines - vive la différence? *Nat Rev Rheumatol*. 2021 Nov;17(11):649-650.
95. Lorenz HM, Froschauer S, Hanke R, Hellmich B, Krause A, Lakomek HJ, Kötter I, Strunk J, Voormann A, Zinke S. Publicity campaign rheuma2025 of the Union for Rheumatology. *Z Rheumatol*. 2022 Apr 7:1-4.
96. Moosig F, Holle J, Hellmich B. Small vessels, great progress. *Z Rheumatol*. 2022 May;81(4):267-269.
97. Holle JU, Hellmich B, Moosig F. Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis. *Z Rheumatol*. 2022 May;81(4):280-285.
98. Hellmich B, Holle J, Moosig F. Eosinophilic granulomatosis with polyangiitis : Update on classification and management. *Z Rheumatol*. 2022 May;81(4):286-299.
99. Hellmich B, Henes JC. Biologics for connective tissue diseases and vasculitides. *Internist (Berl)*. 2022 Feb;63(2):143-154.
100. Kraemer M, Becker J, Bley TA, Steinbrecher A, Minnerup J, Hellmich B. Diagnose und Therapie der Riesenzellarteriitis. *Nervenarzt*. 2022 Aug;93(8):819-827.
101. Lorenz HM, Froschauer S, Hanke R, Hellmich B, Krause A, Lakomek HJ, Kötter I, Strunk J, Voormann A, Zinke S. Publicity campaign rheuma2025 of the Union for Rheumatology]. *Z Rheumatol*. 2022 Aug;81(6):487-491

c) Bücher und Buchbeiträge

1. Hellmich B. Fallbuch Innere Medizin. 1. Auflage. Thieme Verlag Stuttgart 2003; 400 Seiten.
2. Hellmich B. Fallbuch Innere Medizin. 2. Auflage. Thieme Verlag Stuttgart 2005; 402 Seiten.
3. Hellmich B. Fallbuch Innere Medizin. 3. aktualisierte Auflage. Thieme Verlag Stuttgart 2007; 442 Seiten.
4. Hellmich B. Fallbuch Innere Medizin. 4. aktualisierte Auflage. Thieme Verlag Stuttgart 2013; 442 Seiten
5. Hellmich B. Fallbuch Innere Medizin. 5. aktualisierte Auflage. Thieme Verlag Stuttgart 2017;
6. Hellmich B. Fallbuch Innere Medizin. 6. aktualisierte Auflage. Thieme Verlag Stuttgart 2020;
7. Schmidt KL, unter Mitarbeit von Hellmich B, Manger B, Tillmann K und Truckenbrodt H. Checkliste Rheumatologie, Georg Thieme Verlag (Stuttgart, New York) 2000.
8. Manger B, Häfner R, Hellmich B, Schulze-Koops H, Tilmann K, Tuckenbrodt H (2005) Checkliste Rheumatologie XXL, 3. überarbeitete Auflage. Georg Thieme Verlag, Stuttgart, 680 Seiten.
9. Ahmadi K, Hellmich B, Gross WL. Systemischer Lupus erythematodes. In: Springer Lexikon Diagnose und Therapie (Hrsg: P. Reuter), Springer Verlag, !. Auflage 2006: 935-939.
10. Hellmich B, Gross WL, de Groot K. Vaskulitiden mit Nierenbeteiligung. In: Nephrologie in Klinik und Praxis (Ed.: F. Riesler). 19. Erg. Lfg. 06/04: 1-16.
11. Hellmich B, Gross WL (2005). Churg Strauss Syndrom. In Dierkesmann R et al. (Hrsg) Rationelle Diagnostik und Therapie in der Inneren Medizin. Lieferung 19, I 16, Seite 1-3.
12. Hellmich B. Entzündliche Gefässerkrankungen. In: Gefässmedizin (Hrsg: Cissarek, Kröger, Santosa), ABW Wissenschaftsverlag 2009, Seite 360-395.
13. Gross WL, Hellmich B. Erkrankungen aus dem rheumatischen Formenkreis. In: Innere Medizin, 6. Auflage (Hrsg: Calssen, Dieh, Kochsiek), Urban und Fischer Verlag 2009, Seite 792-837.
14. Hellmich B et al. Vaskulitiden. In Kreuter etl al. Seltene Lungenerkrankungen. Springer Verlag 2022.

d) Sonstige Buchbeiträge (Tagungsbände)

1. Hellmich B., Kemen M., Neumann H.A.: Phagocytosis of polymorphonuclear leukocytes and monocytes in septic shock .In: The Immune Consequences of Trauma, Shock and Sepsis, Vol 2/2.,E. Faist...(Eds.), Pabst Science Publishers : 898 - 906 (1996).
2. Hellmich B., Neumann H.A., Grumpe E.M., Baier J., Kemen M.: Leukocyte function in severely ill patients: the influence of an Arginine-supplemented diet on phagocytosis in vitro.In: Proceedings of the 7th European Congress on Intensive Care Medicine, Mutz N.. (Eds.), 1st ed., Monduzi Edditore (Bologna): 153-156(1994).